Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series

被引：0
|
作者：
Schultz, M.
Richardson, R.
Patterson, K.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Neuromuscular Disorders; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
197
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [41] Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
    Chand, Deepa
    Mohr, Franziska
    McMillan, Hugh
    Tukov, Francis Fonyuy
    Montgomery, Kyle
    Kleyn, Aaron
    Sun, Rui
    Tauscher-Wisniewski, Sitra
    Kaufmann, Petra
    Kullak-Ublick, Gerd
    JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 560 - 566
  • [42] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
  • [43] Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
    Mirea, Andrada
    Shelby, Elena-Silvia
    Axente, Mihaela
    Badina, Mihaela
    Padure, Liliana
    Leanca, Madalina
    Dima, Vlad
    Sporea, Corina
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [44] Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec - A Single Centre Experience
    Friese, Johannes
    Geitmann, Stephanie
    Holzwarth, Dorothea
    Mueller, Nicole
    Sassen, Robert
    Baur, Ute
    Adler, Kristin
    Kirschner, Janbernd
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (02) : 209 - 216
  • [45] Outcomes in patients with spinal muscular atrophy (SMA) and four or more SMN2 copies treated with onasemnogene abeparvovec: findings from RESTORE
    Finkel, R.
    Benguerba, K.
    Gehani, M.
    Raju, D.
    Faulkner, E.
    LaMarca, N.
    Servais, L.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S133 - S133
  • [46] Onasemnogene abeparvovec gene-replacement therapy for spinal muscular atrophy: From bench to bedside
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    HUMAN GENE THERAPY, 2019, 30 (08) : A9 - A9
  • [47] ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY: FROM BENCH TO BEDSIDE
    Kaufmann, P.
    Kausar, I.
    Foust, K. D.
    Kaspar, A.
    Kaspar, B. K.
    Mendell, J. R.
    THORAX, 2019, 74 : A109 - A109
  • [48] Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
    Kichula, Elizabeth A.
    Proud, Crystal M.
    Farrar, Michelle A.
    Kwon, Jennifer M.
    Saito, Kayoko
    Desguerre, Isabelle
    McMillan, Hugh J.
    MUSCLE & NERVE, 2021, 64 (04) : 413 - 427
  • [49] Interim results from RESPOND: a study of nusinersen in children with spinal muscular atrophy (SMA) previously treated with onasemnogene abeparvovec (OA)
    Masson, R.
    Proud, C.
    Finkel, R.
    Parsons, J.
    Kuntz, N.
    Foster, R.
    Li, W.
    Chary, S.
    Sohn, J.
    Fradette, S.
    Youn, B.
    Paradis, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [50] Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil
    Fernandes, Brigida Dias
    Rodrigues, Fernanda D'Athayde
    Cirilo, Herica Nubia Cardoso
    Borges, Stefani Sousa
    Krug, Barbara Correa
    Probst, Livia Fernandes
    Zimmermann, Ivan
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 108 - 117
12345